Vantage Market Research report examines the Antibody Drug Conjugates (ADCs) market, forecasting trends and dynamics from 2025 ...

In this interview, Technology Networks spoke with Dr. Lena Jonsson, product strategy manager at Cytiva, to explore the ...

CSPC PHARMA (01093.HK) announced that the Investigational New Drug (IND) application for SYS6041 (Antibody-Drug Conjugate) ...

In this video, Robert DeBernardo, MD, shares insight on antibody-drug conjugates as treatment for patients with cancer, a topic discussed at Society of Gynecologic Oncology Annual Meeting on Women’s ...

ALX2004 is a potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid ...

Antibody-drug conjugates are a significant evolution in drug development landscape: Dr. Kenneth Barr: Nandita Vijayasimha, Bengaluru Saturday, April 12, 2025, 08:00 Hrs [IST] Anti ...

German scientist Paul Ehrlich introduced a groundbreaking concept to the world: chemical compounds could be engineered to ...

CHF 27 million investment significantly bolsters Boehringer's ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company’s aim of transforming the lives of people with cancer.

Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer. Antibody-drug conjugates, or ADCs, have had a tremendous impact on the ...

IPH4502 is a novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) conjugated to exatecan targeting Nectin-4, a cell adhesion molecule that is overexpressed in several ...

CHF 27 million investment significantly bolsters Boehringer’s ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company’s aim of transforming the lives of people with ...